Set Up FREE Account Submit Release. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Bristol-Myers Squibb (BMS) Archives - The Knox Reports Bristol Myers Squibb is adjusting its 2022 GAAP line-item guidance as follows: Adjusting GAAP EPS guidance primarily due to the acquisition of Turning Point and reaffirming non-GAAP EPS guidance. Bristol-Myers Squibb Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 . With a focus on Global Sotalol Market and general market expansion and trends for 2022-2030, by Marketreports.info reports on the main elements and current market trends. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the final dose. For fiscal 2021, it had a total revenue of $46.4 billion. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. Century Therapeutics and Bristol Myers Squibb Enter into a Strategic COMMANDS (NCT03682536) is a Phase 3, open-label, randomized study evaluating the efficacy and safety of Reblozyl versus epoetin alfa, for the treatment of anemia due to very low-, low- or intermediate-risk (IPSS-R) myelodysplastic syndrome (MDS) in patients who are red blood cell (RBC) transfusion dependent and were erythropoiesis stimulating agent (ESA) nave. (c) Includes amortization of purchase price adjustments to Celgene debt. Dial-in participants can register for the conference call here and once registration is complete, will not require operator assistance to connect. Positive topline results from the Phase 3 KarMMa-3 trial showed treatment with Abecma compared to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen met its primary endpoint of demonstrating a statistically significant improvement in progression-free survival. Press Release (PDF) Reports Third Quarter Revenues of $11.2 Billion. Media Inquiries: Bristol-Myers Squibb Reports Q4 and Full Year Results for 2019 SEPTEMBER 30, 2022 AND 2021. Revenues for in-line products in the third quarter were $8.1 billion compared to $7.7 billion in the prior year period, representing an increase of 5% or 10% when adjusted for foreign exchange. 99.1 Press release of Bristol-Myers Squibb Company dated October 25, 2022. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. To learn more about our priorities and goals, please visit our latest ESG report. Bristol Myers Squibb Announces New Sotyktu (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, divestiture gains or losses, stock compensation resulting from acquisition-related equity awards, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. When adjusted for foreign exchange impacts, international revenues decreased 14%, primarily due to lower demand of. Marketing, selling and administrative expenses increased 8% to $1.9 billion in the quarter, primarily due to higher costs to support new product launches and cash settlement of Turning Point Therapeutics, Inc. (Turning Point) unvested stock awards, partially offset by foreign exchange impacts. Celgene common stock ceased trading as of the close of trading today. The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the companys baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. 2010;5(11). Gross margin decreased from 80.3% to 79.0% and on a non-GAAP basis, decreased from 81.1% to 79.8% in the quarter primarily due to product mix, partially offset by foreign exchange impacts and related hedging settlements. The FDA assigned a Prescription Drug User Fee Act goal date of June 16, 2023. Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular In addition, non-GAAP gross margin, which is gross profit excluding certain specified items, as a percentage of revenues, non-GAAP operating expenses, which is marketing, selling and administrative and research and development expenses excluding certain specified items, non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. Reblozyl, the first erythroid maturation agent, met primary and key secondary endpoints in the first-line treatment of patients with very low/low/intermediate-risk myelodysplastic syndromes. 888-776-0942 from 8 AM - 10 PM ET. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol CSRWire - A Beacon of Hope Search Press Releases. Global Biopharmaceutical Company - Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over seriousdiseases. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31 . Its products focus on oncology, immunology and cardiovascular conditions. Beginning with the first quarter of 2022, significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from our non-GAAP financial measures. Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. On November 21, 2019, newly issued Bristol-Myers Squibb shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol BMYRT., This is an exciting day for Bristol-Myers Squibb as we bring together the leading science, innovative medicines and incredible talent of Bristol-Myers Squibb and Celgene to create a leading biopharma company, said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. Two-year results from the POETYK PSO long-term extension trial demonstrated that clinical efficacy was maintained with continuous Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. 2022, December 31, Cautionary Statement Regarding Forward-Looking Statements. Monitor patients with beta thalassemia at initiation and during treatment for symptoms and signs or complications resulting from the EMH masses and treat according to clinical guidelines. Cancer can have a relentless grasp on many parts of a patients life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Hydroxyurea Market 2022 Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities till 2031. Mr. Bonney and Dr. Haller served on Celgenes Board of Directors until the closing of the transaction. 09/10/2022. Kura has agreed to sell 1,370,171 shares to Bristol Myers Squibb at a price of $18.25 per share for gross proceeds of $25 million. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Former Bristol-Myers Squibb Senior Executive Pleads Guilty for Role in Bristol Myers Squibb BMY -0.01% + Free Alerts today announced new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating clinical efficacy was maintained with. On a non-GAAP basis, marketing, selling and administrative expenses increased 4% to $1.9 billion primarily due to higher investments to support new product launches, partially offset by foreign exchange impacts. In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. September 30, 2022, Quarter Ended Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Celldex Therapeutics and Bristol Myers-Squibb Announce Since announcing the transaction on January 3, 2019, there have been a number of tangible advancements toward delivering on the key value drivers for the merger, including: further progress relating to the patent estate for REVLIMID, the U.S. Food and Drug Administration (FDA) approval of INREBIC (fedratinib) for the treatment of certain forms of myelofibrosis, the U.S. FDA approval of REBLOZYL (luspatercept-aamt) for the treatment of anemia in certain adult patients with beta thalassemia, and regulatory filings of luspatercept and ozanimod in the U.S. and Europe. FOR IMMEDIATE RELEASE2015-229. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future. Learn about how were working for those who rely on our medicines, those who live in our communities and those who work for our company. Bristol-Myers Squibb Company (BMY) Latest Press Releases F/X Impact), Total In-Line Products and New Product Portfolio Revenue. Bristol-Myers Squibb (BMS) Home - Bristol-Myers Squibb . . ** In excess of +/- 100% These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that Reblozyl (luspatercept-aamt) may not receive regulatory approval for the additional indication described in this release in the currently anticipated timeline or at all, that any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such product candidate for such additional indication described in this release will be commercially successful. Thinking about trading options or stock in Moderna, Bristol-Myers The Bristol-Myers Squibb Company ( BMS) is an American multinational pharmaceutical company. AS OF SEPTEMBER 30, 2022 AND DECEMBER 31, 2021, September 30, Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Bristol-Myers Squibb Company Common Stock (BMY) Press Releases - Nasdaq Kura Oncology Announces Financing Transactions with Bristol Myers Press Releases. Bristol Myers Squibb TOKYO AND NEW YORK, June 18, 2021 -- Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). ET during which company executives will review the quarterly financial results and address inquiries from investors and analysts. Bristol-Myers Squibb Company (BMY) Latest Press Releases - Yahoo! This report lays out Bristol Myers Squibbs efforts and progress towards advancing access to healthcare and health equity globally through its own efforts and in partnership with other stakeholders. media@bms.com Based on this success, Bristol Myers Squibb and Evotec extend and . 2021. Report: Exploring Fundamental Drivers Behind Bristol-Myers Bristol-Myers Squibb anticipates that all repurchases under the ASR will be completed by the end of the second quarter of 2020. Press Releases RSS Feeds Unsubscribe to News Email Alerts - Bristol Myers Squibb Subscribe to New Email Alerts - Bristol Myers Squibb Our Stories All Patients People Science . Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine,. Forward-Looking Statement of Bristol Myers Squibb. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2021, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange . About Molecular Templates. At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. Through the transaction, the company gained repotrectinib, a next-generation, potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. 2021, Cash, cash equivalents and marketable debt securities, Media: media@bms.com Bristol-Myers Squibb Company Agrees to Pay $150 Million to Settle Fraud Bolivia Bristol-Myers Squibb News Topics For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. forward-looking statements in the press release should be evaluated together with the many uncertainties that affect bristol-myers squibb's business, particularly those identified in the cautionary factors discussion in bristol-myers squibb's annual report on form 10-k for the year ended december 31, 2014, its quarterly reports on form 10-q, and Bristol Myers Squibb - Bristol Myers Squibb Reports Third Quarter News Press Releases Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million BMY, HTGC, KURA | 3 days ago - $25 million equity investment from Bristol Myers Squibb at $18.25 per share - - Term loan facility from Hercules Capital provides up to $125 million - anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Key secondary endpoints include RBC-TI for 24 weeks, RBC-TI 12 weeks and erythroid response of at least 8 weeks during weeks 1-24 of the study. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. A subset of BMS.com, Our Storiesis where we share the work our global community of colleagues are doing around the worldtohelp patients and advance scientific innovation. Bristol Myers Squibb - Iframes - Press Releases - BMS The GAAP effective tax rate changed from 28.0% to 27.2% in the quarter and non-GAAP effective tax rate changed from 14.6% to 16.9% in the quarter due to changes in previously estimated annual effective tax rates due to jurisdictional earnings mix. Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022, which reflect strong in-line and new product portfolio growth. Oct 21, 2022 (PRNewswire via COMTEX) -- PR Newswire NEW YORK, Oct. 21, 2022 Amortization of acquired intangible assets decreased 5% to $2.4 billion in the quarter, primarily due to a change in the expected expiration of the market exclusivity period for. Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company January 03, 2019 Download this Press Release Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease Myelodysplastic syndromes (MDS) are a group of closely related blood cancers characterized by ineffective production of healthy red blood cells, white blood cells and platelets, which can lead to anemia and frequent or severe infections.1,2 People with MDS who develop anemia often require regular blood transfusions to increase the number of healthy red blood cells in circulation.3 Frequent transfusions are associated with an increased risk of iron overload, transfusion reactions and infections.4. All comparisons are made versus the same period in 2021 unless otherwise stated. Our nine new product launches over the last three years including three first-in-class launches this year, combined with progress in our robust and diverse product pipeline, have built a strong foundation for our company. Kura has agreed to sell 1,370,171 shares to Bristol Myers Squibb at a price of $18.25 per share for gross proceeds of $25 million. Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases. Investors and the public can also access the live webcast by dialing in the U.S. toll free 888-330-2388 or international +1 240-789-2707, confirmation code: 24168. (, In September, the company issued our 2021 Global Inclusion and Diversity Report which outlines our strategy and the progress we have made toward our 2025 Inclusion & Diversity and Health Equity Commitments, among others. In adult patients with MDS with normal baseline blood pressure, 26 (29.9%) patients developed SBP 130 mm Hg and 23 (16.4%) patients developed DBP 80 mm Hg. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. Across clinical studies, the incidence of Grade 3 to 4 hypertension ranged from 1.8% to 8.6%. This plea agreement follows BMSs June 11, 2007, agreement to plead guilty and pay a $1 million criminal fine the maximum fine permitted by . The phase 3 COMMANDS trial (NCT03682536), evaluating luspatercept-aamt (Reblozyl; Bristol Myers Squibb), met its primary endpoint of a highly statistically significant and clinically meaningful improvement in red blood cell transfusion independence (RBC-TI) with concurrent hemoglobin (Hb) increase in the first-line for individuals with very low-, low-, or intermediate-risk myelodysplastic . Phoenix, AZ. Bristol Myers Squibb Announces Positive Topline Results of Phase 3 To learn more, please visit our latest. Upon completion of the acquisition, pursuant to the terms of the merger agreement, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol Myers Squibb's Reblozyl Meets Primary Endpoints as First-Line Bristol-Myers Squibb expects to fund the repurchase with cash on-hand. Reblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.5 Reblozyl is being developed and commercialized through a global collaboration with Merck following Mercks acquisition of Acceleron Pharma, Inc. in November 2021. No forward-looking statement can be guaranteed, including that the companys future clinical studies will support the data described in this release, product candidates will receive necessary clinical and manufacturing regulatory approvals, pipeline products will prove to be commercially successful, clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes, or that contractual milestones will be achieved. Current and archived releases and publications are available. I am excited about the opportunities for our current employees and the new colleagues that we welcome to the Company as we work together to deliver innovative medicines to patients.. Acquired IPRD in the same period a year ago was primarily related to the Agenus licensing transaction ($200 million). We routinely post important information for investors on our website, BMS.com, in the Investors section. Combined with our financial strength and talented employees, Bristol Myers Squibb is well positioned for growth and to advance new medicines for patients.. Visit us at. 1Acquired IPRD refers to certain in-process research and development (Acquired IPRD) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights. Press Release - Bristol-Myers Squibb - bms.com (a) Includes over-the-counter (OTC) products, royalty revenue and mature products. The 2022 non-GAAP EPS guidance is further explained under Use of Non-GAAP Financial Information. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. Bristol Myers Squibb Announces Positive Topline Results of Phase 3 Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.